No insider purchase over the last 90 days. The latest, by 라정찬, was filed 27 Mar 2026.
Who traded when
BuySaleSince the insiders bought
- +23.0%Entry ₩17,720 · Close 30 Oct 2026 ₩21,800
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 114,566 shares@ ₩17,457.04870.12% mcap100.0% of flowShareKRXDART:20260327000421Canonical exit: 24 Jun 2026 (T+90)
- 54,664 shares@ ₩18,238.000.067% mcap100.0% of flowShareKRXDART:20260320000533Canonical exit: 18 Jun 2026 (T+90)
- ●Executives0DART
- 10,000 sharesShareKRXDART:20251226000512
- 9,601 sharesShareKRXDART:20250926000802
- 3,000 sharesShareKRXDART:20250509000837Canonical exit: 7 Aug 2025 (T+90)
- 481,771 sharesKRXDART:20240719000494Canonical exit: 14 Oct 2024 (T+90)
- ShareKRXDART:20240719000472
- ShareKRXDART:20230829000688
- ●Executives0DART
- ShareKRXDART:20230630000796
- 481,771 sharesKRXDART:20230602000528Canonical exit: 29 Aug 2023 (T+90)
- 481,771 sharesKRXDART:20230518000329Canonical exit: 9 Aug 2023 (T+90)
- ShareKRXDART:20230518000334
- ●Executives0DART
- 600,000 sharesKRXDART:20230214001372
- 481,771 sharesKRXDART:20221021000193Canonical exit: 19 Jan 2023 (T+90)
- ShareKRXDART:20221004000373
- ShareKRXDART:20221004000360
- ShareKRXDART:20221004000220
- 481,771 sharesKRXDART:20220915000478Canonical exit: 14 Dec 2022 (T+90)
- ShareKRXDART:20220915000482
- 481,771 sharesKRXDART:20220617000396Canonical exit: 15 Sept 2022 (T+90)
- ●Executives0DART
- ●Executives0DART
25 of 43 declarations
About NatureCell Co.,Ltd.
The two largest purchases in the NatureCell Co.,Ltd. (네이처셀) record are recent and share a signature: EUR 1,151,991 on March 26, 2026 and EUR 577,241 on March 20, 2026, both filed by 라정찬, listed as 대표이사 (representative director). They are the only 2 purchases that carry an amount, for EUR 1.7 million in total.
The Korean healthcare company, with a market capitalisation of KRW 1,536.8 billion, has 43 filings published between March 2, 2021 and March 27, 2026. 라정찬 files 20 of them, including 2 purchases and 1 sale. 알앤엘재생의학연구소, filed as 대량보유자 (large holder), files 14, including 12 purchases and 1 sale. 변대중, filed as 사장(대표이사), has 2 sales, and 박상철, filed as 사내이사 (inside director), 1 purchase.
Read moreShow less
Overall, 15 purchases and 4 sales make 79% purchases among open-market trades, and 24 filings are of another kind. The pace has slowed: 17 filings in 2021, 2 in 2024, 3 in 2025 and 3 in 2026. The last twelve months hold 4 filings, including 2 purchases and 1 sale. Taking the 9 filings with a known delay, publication follows the trade by a median of 3 days.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
